Gastric Emptying in Healthy Volunteers and GLP-1 Agonist Users
NCT ID: NCT06987669
Last Updated: 2025-05-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
155 participants
OBSERVATIONAL
2025-05-17
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Is the kinetic after a standard breakfast that includes ( avocado and eggs: high fat) as fast as a standard meal that does not involve this food?
* Is a clear liquid diet of 18 to 24 hours enough to be an empty-stomach, assessed by Ultrasound in patients on GLP1 agonist?
Participants will be asked to do:
-A baseline Gastric US will be performed for healthy volunteers, and then they will have a standardized breakfast. An hourly or bihourly assessment will be done by the US.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Gastric Ultrasound To Assess Gastric Contents In Patients On Semaglutide Therapy
NCT06292065
Body Surface Gastric Mapping in Patients on Semaglutide
NCT06401746
The Semaglutide Study
NCT06420739
Investigation of the Evolution of Gastric Emptying by Gastric Ultra Sonography in Patients Treated With GLP-1 Receptor Agonists on a 7 Days Pausing Period.
NCT06388213
Effects of Beginning a GLP1-Agonist Therapy on Residual Gastric Content and Gastric Emptying
NCT06659159
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The main goal is to gather evidence to determine the optimal fasting period and dietary regimen to ensure safe outpatient surgery without increasing the risk of aspiration.Ultrasound gastric content assessment is a highly accessible, bedside, cost-free, and low-risk tool for anesthesiologists. The increased use of these drugs in surgical patients and the lack of international consensus on their discontinuation and fasting protocols before surgery necessitate further study. Our hypothesis is that GLP-1 analogue users (for weight loss or diabetes) have significantly slower gastric emptying, but a 24-hour liquid regimen may be sufficient to ensure an empty stomach and safe elective surgery.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy volunteers after high fat standardized breakfast
GUS will be made
Gastric Ultrasound
A gastric ultrasound will be performed to determine the state of the stomach. Empty, clear fluids, solid, and in case of fluid, the amount of it ( using free tracing)
Patients on GLP-1 agonist
Patients on GLP-1 agonist after clear fluids diet of 18/24 hrs. GUS will be made.
Gastric Ultrasound
A gastric ultrasound will be performed to determine the state of the stomach. Empty, clear fluids, solid, and in case of fluid, the amount of it ( using free tracing)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Gastric Ultrasound
A gastric ultrasound will be performed to determine the state of the stomach. Empty, clear fluids, solid, and in case of fluid, the amount of it ( using free tracing)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthy volunteers or semaglutide users
Exclusion Criteria
* Hiatal hernia
* Impairment to give consent
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Clinica Alemana de Santiago
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Javiera Vargas
Medical Doctor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Cristian Arzola, MD, MSc
Role: STUDY_CHAIR
Universidad de Toronto
Juan Pablo Ghiringelli
Role: STUDY_DIRECTOR
Universidad de Valparaiso
Miguel vega, MD
Role: STUDY_DIRECTOR
Universidad del Desarrollo
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-100
Identifier Type: OTHER
Identifier Source: secondary_id
ID1406
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.